HDAC9 and lymphoma: A medicinal chemistry effort aimed at incorporating HDAC inhibitory function into a PI3K inhibitor pharmacophore led to the identification of fimepinostat (CUDC-907; Figure 8), a PI3K/HDAC dual inhibitor for the treatment of lymphoid cancers [173,174,175].